Outcomes and Therapeutic Management of Bladder Cancer
Material type:![Article](/opac-tmpl/lib/famfamfam/AR.png)
- books978-3-03936-935-5
- 9783039369348
- 9783039369355
- Medicine
- bladder cancer
- robotic-assisted
- open
- radical cystectomy
- survival
- propensity score
- age
- urothelial carcinoma
- outcome
- anesthesia recovery periods
- cognitive impairment
- gamma-cyclodextrins
- neuromuscular blockade
- robotic radical cystectomy
- glycogen
- clear-cell adenocarcinoma
- urinary bladder
- SEER program database
- female
- intracorporeal neobladder
- outcomes
- robotic
- sex-sparing
- methylation
- biomarkers
- FOXA1
- GATA3
- KRT20
- molecular markers
- mRNA
- muscle-invasive bladder cancer
- PCR
- human epidermal growth factor receptor 2
- indoleamine 2,3-dioxygenase
- programmed death ligand-1
- immunotherapy
- nodal disease
- pN1
- neoadjuvant
- adjuvant
- chemotherapy
- n/a
Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
![]() |
OPJGU Sonepat- Campus | E-Books Open Access | Available |
Open Access star Unrestricted online access
Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.
Creative Commons https://creativecommons.org/licenses/by/4.0/ cc https://creativecommons.org/licenses/by/4.0/
English
There are no comments on this title.